Published in Front Oncol on June 13, 2014
Drug-diagnostics co-development in oncology. Front Oncol (2014) 0.77
Personalized health care beyond oncology: new indications for immunoassay-based companion diagnostics. Ann N Y Acad Sci (2015) 0.77
Diapeutic cancer-targeting alkylphosphocholine analogs may advance management of brain malignancies. CNS Oncol (2016) 0.75
Multidisciplinary efforts driving translational theranostics. Theranostics (2014) 0.75
Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials. Drug Des Devel Ther (2015) 0.75
A biological perspective toward the interaction of theranostic nanoparticles with the bloodstream - what needs to be considered? Front Chem (2015) 0.75
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol (2006) 16.25
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov (2010) 7.48
The causes and consequences of genetic heterogeneity in cancer evolution. Nature (2013) 5.91
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol (2008) 5.54
In vivo imaging of siRNA delivery and silencing in tumors. Nat Med (2007) 4.94
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol (2010) 4.62
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res (2004) 4.56
Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res (2007) 3.25
High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res (2001) 2.90
Diversity of Conus neuropeptides. Science (1990) 2.78
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol (2001) 2.71
Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol (2009) 2.25
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol (2013) 1.92
Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia (2002) 1.85
Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun (2007) 1.82
Purification and characterization of chlorotoxin, a chloride channel ligand from the venom of the scorpion. Am J Physiol (1993) 1.77
Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology (2001) 1.75
Chlorotoxin labeled magnetic nanovectors for targeted gene delivery to glioma. ACS Nano (2010) 1.52
Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science (1993) 1.47
Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). Expert Opin Drug Deliv (2007) 1.45
Shifting emphasis from pharmacogenomics to theragnostics. Nat Biotechnol (2006) 1.40
Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects. J Biol Chem (2009) 1.33
From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets. Nat Rev Cancer (2012) 1.32
Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. Ann Oncol (2008) 1.31
Venomics as a drug discovery platform. Expert Rev Proteomics (2009) 1.25
Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2012) 1.25
Molecular imaging of a cancer-targeting theragnostics probe using a nucleolin aptamer- and microRNA-221 molecular beacon-conjugated nanoparticle. Biomaterials (2011) 1.22
Mining the biodiversity of plants: a revolution in the making. Science (2012) 1.21
Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol (2002) 1.20
Assessing the clinical utility of diagnostics used in drug therapy. Clin Pharmacol Ther (2010) 1.16
Characterization of the human folate receptor alpha via novel antibody-based probes. Oncotarget (2011) 1.06
Recent advances in the use of protein transduction domains for the delivery of peptides, proteins and nucleic acids in vivo. Expert Opin Drug Deliv (2005) 1.04
Penetratin improves tumor retention of single-chain antibodies: a novel step toward optimization of radioimmunotherapy of solid tumors. Cancer Res (2005) 1.03
Inhibitors of the anaplastic lymphoma kinase. Expert Opin Investig Drugs (2012) 0.95
Meta-analysis of cancer gene expression signatures reveals new cancer genes, SAGE tags and tumor associated regions of co-regulation. Nucleic Acids Res (2010) 0.94
Crotamine mediates gene delivery into cells through the binding to heparan sulfate proteoglycans. J Biol Chem (2007) 0.94
Brentuximab vedotin for the treatment of CD30+ lymphomas. Immunotherapy (2011) 0.93
Comparison of prognostic genomic predictors in colorectal cancer. PLoS One (2013) 0.90
Diabodies: small bispecific antibody fragments. Cancer Immunol Immunother (1998) 0.89
Agents that bind annexin A2 suppress ocular neovascularization. J Cell Physiol (2010) 0.88
Sphingomyelin is important for the cellular entry and intracellular localization of Helicobacter pylori VacA. Cell Microbiol (2010) 0.86
Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab. EJNMMI Res (2011) 0.82
Understanding the economic value of molecular diagnostic tests: case studies and lessons learned. J Pers Med (2013) 0.79
Advances in targeted therapeutic agents. Expert Opin Drug Discov (2010) 0.77
Techniques for using Bexxar for the treatment of non-Hodgkin's lymphoma. J Nucl Med Technol (2002) 0.77